I think I’m hardly alone in really giving much thought to the medicine I might take if I find myself with a headache or inflamed joint. I’ll certainly have some concern with whether the medicine will take care of the pain or not. But until recently I’ never think beyond that point. But all that changed when I stumbled on an article describing an ongoing court case. An investment banking firm called Laidlaw & Company was in legal battle with a medical research company called Relmada Therapeutics. The case was made more complex by the fact that the court had issued a temporary restraining order and associated injunction against Laidlaw under grounds that they were deliberately spreading misleading information.
It was the injunction which sparked my curiosity. I’m never fond of being told I can’t know more about ongoing news. So I went to Laidlaw’s site in hopes of finding out some more information. The company itself was impressive simply for the age. They were established around 1842. But it wasn’t so much the age as how they documented it that was impressive. They had an entire timeline that listed what they were up to during that lengthy timespan.
It wasn’t until I found the biographies of some senior executives that things really fell in place though. Matthew Eitner and James Ahern both had extensive biographies on the company website. And it was clear that both of them have a deep interest in helping to facilitate medical research. This is really the link between the various complex systems that I’d been looking for. It made sense that large financial powers would need to fund medical studies. And it made equal sense that for that to happen some people at the top of those companies would have to have some strong feelings or sense of responsibility for it. It’s little surprise that in a firm like Laidlaw that this might end up turning into a legal issue if things didn’t turn out as expected.